External quality assessment of Rift Valley fever diagnosis in countries at risk of the disease: African, Indian Ocean and Middle-East regions.

Rift Valley fever virus (RVFV), an arbovirus belonging to the Phlebovirus genus of the Phenuiviridae family, causes the zoonotic and mosquito-borne RVF. The virus, which primarily affects livestock (ruminants and camels) and humans, is at the origin of recent major outbreaks across the African continent (Mauritania, Libya, Sudan), and in the South-Western Indian Ocean (SWIO) islands (Mayotte). In order to be better prepared for upcoming outbreaks, to predict its introduction in RVFV unscathed countries, and to run efficient surveillance programmes, the priority is harmonising and improving the diagnostic capacity of endemic countries and/or countries considered to be at risk of RVF. A serological inter-laboratory proficiency test (PT) was implemented to assess the capacity of veterinary laboratories to detect antibodies against RVFV. A total of 18 laboratories in 13 countries in the Middle East, North Africa, South Africa, and the Indian Ocean participated in the initiative. Two commercial kits and two in-house serological assays for the detection of RVFV specific IgG antibodies were tested. Sixteen of the 18 participating laboratories (88.9%) used commercial kits, the analytical performance of test sensitivity and specificity based on the seroneutralisation test considered as the reference was 100%. The results obtained by the laboratories which used the in-house assay were correct in only one of the two criteria (either sensitivity or specificity). In conclusion, most of the laboratories performed well in detecting RVFV specific IgG antibodies and can therefore be considered to be prepared. Three laboratories in three countries need to improve their detection capacities. Our study demonstrates the importance of conducting regular proficiency tests to evaluate the level of preparedness of countries and of building a network of competent laboratories in terms of laboratory diagnosis to better face future emerging diseases in emergency conditions.

Epidemiological investigations on Trypanosoma evansi infection in dromedary camels in the South of Algeria.

An epidemiological study of Trypanosoma evansi (T. evansi) infection in dromedaries was conducted in four wilayate (localities) of Southern Algeria: Béchar, El Bayadh, Ouargla, Tamanrasset. Between February 2014 and April 2016, 1056 camels of different ages and both sexes from 84 herds were sampled. The prevalence was determined through parasitological examination (Giemsa stained thin smear, GST), serological tests (CATT/T. evansi, ELISA/VSG RoTat 1.2, immune trypanolysis), and molecular tests (T. evansi type A specific RoTat 1.2 PCR and T. evansi type B specific EVAB PCR). The overall prevalence was 2.4 % with GST, 32.4% with CATT/T. evansi, 23.1% with ELISA/VSG RoTat 1.2, 21.0% with immune trypanolysis (TL), 11.2 % with RoTat 1.2 PCR and 0% with EVAB PCR. El Bayadh was the most affected wilaya with 11.8% positives in GST, 74.9% in CATT/T. evansi, 70.1% in ELISA/VSG RoTat 1.2 and 62.2% in immune trypanolysis. Only in Béchar, a non-significantly higher prevalence (13.6%) was observed with RoTat1.2 PCR than in El Bayadh (13.0%). We didn't find any evidence of the presence of T. evansi type B in the study area.

Foot-and-mouth disease outbreaks due to an exotic virus serotype A lineage (A/AFRICA/G-IV) in Algeria in 2017.

This study describes the genetic characterization of serotype A viruses collected during outbreaks of foot-and-mouth disease (FMD) that occurred in Algeria in 2017. These are the first reports of clinical cases due to this serotype in the country since 1977. One complete genomic sequence (comprising 8,119 nucleotides) and three additional near-complete genomic sequences were generated. Phylogenetic analyses demonstrated that these viruses were classified within the A/AFRICA/G-IV lineage, most closely related to viruses circulating in Nigeria between 2009 and 2015. These unexpected results motivate further studies to define the precise pathways by which this viral lineage has been introduced into North Africa in order to understand risks of future disease incursions into the region.